Shenzhen Salubris Pharmaceuticals Management
Management criteria checks 4/4
Shenzhen Salubris Pharmaceuticals' CEO is Jie Yan, appointed in Sep 2022, has a tenure of 2.25 years. directly owns 0.012% of the company’s shares, worth CN¥4.37M. The average tenure of the management team and the board of directors is 8 years and 7.8 years respectively.
Key information
Jie Yan
Chief executive officer
CN¥1.7m
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 2.3yrs |
| CEO ownership | 0.01% |
| Management average tenure | 8yrs |
| Board average tenure | 7.8yrs |
Recent management updates
Recent updates
Is Shenzhen Salubris Pharmaceuticals Co., Ltd. (SZSE:002294) Trading At A 29% Discount?
Dec 18
Shenzhen Salubris Pharmaceuticals Co., Ltd.'s (SZSE:002294) Share Price Could Signal Some Risk
Nov 29These 4 Measures Indicate That Shenzhen Salubris Pharmaceuticals (SZSE:002294) Is Using Debt Safely
Nov 11We Think That There Are More Issues For Shenzhen Salubris Pharmaceuticals (SZSE:002294) Than Just Sluggish Earnings
Sep 02What Shenzhen Salubris Pharmaceuticals Co., Ltd.'s (SZSE:002294) P/E Is Not Telling You
Aug 23Are Investors Undervaluing Shenzhen Salubris Pharmaceuticals Co., Ltd. (SZSE:002294) By 21%?
Aug 02Shenzhen Salubris Pharmaceuticals Co., Ltd.'s (SZSE:002294) Share Price Not Quite Adding Up
May 22A Look At The Fair Value Of Shenzhen Salubris Pharmaceuticals Co., Ltd. (SZSE:002294)
Apr 17Is Shenzhen Salubris Pharmaceuticals (SZSE:002294) A Risky Investment?
Feb 28CEO
Jie Yan (52 yo)
2.3yrs
Tenure
CN¥1,744,500
Compensation
Mr. Jie Yan had been Deputy General Manager at Shenzhen Salubris Pharmaceuticals Co., Ltd. since October 11, 2013 until September 23, 2022 and has been its Non- Independent Director since February 9, 2018...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| GM & Director | 2.3yrs | CN¥1.74m | 0.012% CN¥ 4.4m | |
| CFO, Accounting Supervisor & Financial Manager | 3yrs | CN¥1.31m | no data | |
| Deputy General Manager | 17.5yrs | CN¥963.70k | no data | |
| Secretary of the Board of Directors & Non Independent Director | 17.2yrs | CN¥936.70k | 0.011% CN¥ 3.9m | |
| Deputy General Manager | 8yrs | CN¥1.05m | 0.0075% CN¥ 2.7m | |
| Chief Medical Officer | no data | no data | no data |
8.0yrs
Average Tenure
52yo
Average Age
Experienced Management: 002294's management team is seasoned and experienced (8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| GM & Director | 6.8yrs | CN¥1.74m | 0.012% CN¥ 4.4m | |
| Secretary of the Board of Directors & Non Independent Director | 14.3yrs | CN¥936.70k | 0.011% CN¥ 3.9m | |
| Director | 17.5yrs | no data | no data | |
| Chairman | 17.5yrs | CN¥1.55m | no data | |
| Independent Director | 3.7yrs | CN¥120.00k | no data | |
| Independent Director | 4.9yrs | CN¥120.00k | no data | |
| Chairman of the Supervisory Board | 8yrs | no data | no data | |
| Independent Director | 3yrs | CN¥120.00k | no data | |
| Supervisor | 7.8yrs | no data | no data |
7.8yrs
Average Tenure
52yo
Average Age
Experienced Board: 002294's board of directors are considered experienced (7.8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 09:30 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Shenzhen Salubris Pharmaceuticals Co., Ltd. is covered by 23 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Zhi Xue Diao | Avic Securities Co., Ltd |
| Peng Yan | Changjiang Securities Co. LTD. |
| Liehai Xu | China Merchants Securities Co. Ltd. |